Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2

被引:80
|
作者
Brazier, John E. [1 ]
Mulhern, Brendan J. [1 ,2 ]
Bjorner, Jakob B. [1 ,3 ,4 ]
Gandek, Barbara [5 ,6 ]
Rowen, Donna [1 ]
Alonso, Jordi [7 ,8 ,9 ]
Vilagut, Gemma [7 ,9 ]
Ware, John E. [5 ,6 ]
机构
[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[2] Univ Technol Sydney, Ctr Hlth Econ Res & Evaluat, Sydney, NSW, Australia
[3] OptumInsight, Lincoln, RI USA
[4] Univ Copenhagen, Dept Publ Hlth, Copenhagen, Denmark
[5] John Ware Res Grp, Watertown, MA USA
[6] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA
[7] IMIM Inst Hosp Mar Invest Med, Hlth Serv Res Grp, Barcelona, Spain
[8] Pompeu Fabra Univ UPF, Barcelona, Spain
[9] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain
关键词
SF-36; SF-6D; utilities; quality adjusted life year; Rasch analysis; PREFERENCE-BASED MEASURES; QUALITY-OF-LIFE; 10; COUNTRIES; VALUE SET; UTILITY; VALIDITY; OUTCOMES; EQ-5D; RELIABILITY;
D O I
10.1097/MLR.0000000000001325
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective:The objective of this study was to develop the classification system for version of the SF-6D (SF-6Dv2) from the SF-36v2. SF-6Dv2 is an improved version of SF-6D, one of the most widely used generic measures of health for the calculation of quality-adjusted life years.Study Design and Setting:A 3-step process was undertaken to generate a new classification system: (1) factor analysis to establish dimensionality; (2) Rasch analysis to understand item performance; and (3) tests of differential item function. To evaluate robustness, Rasch analyses were performed in multiple subsets of 2 large cross-sectional datasets from recently discharged hospital patients and online patient samples.Results:On the basis of factor analysis, other psychometric evidence, cross-cultural considerations, and amenability to valuation, the 6-dimension classification used in SF-6D was maintained. SF-6Dv2 resulted in the following modifications to SF-6D: a simpler classification of physical function with clearer separation between levels; a more detailed 5-level description of role limitations; using negative wording to describe vitality; and using pain severity rather than pain interference.Conclusions:The SF-6Dv2 classification system describes more distinct levels of health than SF-6D, changes the descriptions used for a number of dimensions and provides clearer wording for health state valuation. The second stage of the study has developed a utility value set using discrete choice methods so that the measure can be used in health technology assessment. Further work should investigate the psychometric characteristics of the new instrument.
引用
收藏
页码:557 / 565
页数:9
相关论文
共 50 条
  • [1] Developing version 2 of the SF-6D: The health state classification system
    Mulhern, Brendan
    Brazier, John E.
    [J]. QUALITY OF LIFE RESEARCH, 2014, 23 : 49 - 49
  • [2] Is Health Preference Derived from the SF-36v2 Equivalent to that Measured by the SF-6D Health Survey?
    Lam, Cindy L.
    Wong, Carlos K.
    Lam, Elegance T.
    [J]. QUALITY OF LIFE RESEARCH, 2010, 19 : 105 - 105
  • [3] The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
    David G. T. Whitehurst
    John E. Brazier
    Rosalie Viney
    Brendan J. Mulhern
    [J]. PharmacoEconomics, 2020, 38 : 1283 - 1288
  • [4] The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?
    Whitehurst, David G. T.
    Brazier, John E.
    Viney, Rosalie
    Mulhern, Brendan J.
    [J]. PHARMACOECONOMICS, 2020, 38 (12) : 1283 - 1288
  • [5] A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
    McDool, Emily
    Mukuria, Clara
    Brazier, John
    [J]. PHARMACOECONOMICS, 2021, 39 (08) : 929 - 940
  • [6] A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
    Emily McDool
    Clara Mukuria
    John Brazier
    [J]. PharmacoEconomics, 2021, 39 : 929 - 940
  • [7] Correction to: A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population
    Emily McDool
    Clara Mukuria
    John Brazier
    [J]. PharmacoEconomics, 2022, 40 : 139 - 139
  • [8] Valuing the SF-6D Version 2 in Canada
    Bansback, Nick
    Mulhern, Brendan
    Sawatzky, Richard
    Brazier, John
    Whitehurst, David G.
    [J]. QUALITY OF LIFE RESEARCH, 2015, 24 : 180 - 181
  • [9] DERIVATION OF INTERPRETATION THRESHOLDS FOR THE SF-36V2® HEALTH SURVEY (SF-36V2) IN RHEUMATOID ARTHRITIS
    Chen, W. H.
    Rendas-Baum, R.
    Lin, X.
    Kosinski, M.
    Bjorner, J. B.
    Bracher, M.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S247 - S247
  • [10] Comparison of four approaches in eliciting health state utilities with SF-6Dv2
    Ameri, Hosein
    Poder, Thomas G.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2024,